Zegbeh Jallah
Stock Analyst at Capital One
(2.99)
# 1,421
Out of 4,944 analysts
24
Total ratings
36.36%
Success rate
120.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Zegbeh Jallah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgrades: Overweight | $100 | $2.09 | +4,684.69% | 2 | Dec 27, 2023 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $44 | $10.75 | +309.30% | 1 | Dec 11, 2023 | |
| KOD Kodiak Sciences | Upgrades: Overweight | n/a | $8.52 | - | 5 | Nov 17, 2023 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $29 | $23.62 | +22.80% | 2 | Dec 28, 2022 | |
| RAPT RAPT Therapeutics | Initiates: Overweight | $384 | $10.90 | +3,422.94% | 2 | Sep 21, 2022 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $101 → $70 | $6.85 | +921.90% | 2 | May 12, 2022 | |
| RZLT Rezolute | Initiates: Buy | $21 | $6.20 | +238.71% | 1 | Sep 8, 2021 | |
| ARVN Arvinas | Maintains: Buy | $120 → $135 | $6.80 | +1,886.75% | 2 | Aug 9, 2021 | |
| DARE Daré Bioscience | Maintains: Buy | $108 → $132 | $2.03 | +6,402.46% | 1 | Jun 30, 2021 | |
| OCGN Ocugen | Downgrades: Neutral | $10 → $6 | $1.03 | +482.52% | 2 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $55 | $12.25 | +348.98% | 1 | Feb 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $3.67 | - | 1 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.43 | +1,743.32% | 1 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $600 | $2.58 | +23,155.81% | 1 | Dec 18, 2019 |
Outlook Therapeutics
Dec 27, 2023
Upgrades: Overweight
Price Target: $100
Current: $2.09
Upside: +4,684.69%
EyePoint Pharmaceuticals
Dec 11, 2023
Initiates: Overweight
Price Target: $44
Current: $10.75
Upside: +309.30%
Kodiak Sciences
Nov 17, 2023
Upgrades: Overweight
Price Target: n/a
Current: $8.52
Upside: -
IDEAYA Biosciences
Dec 28, 2022
Initiates: Overweight
Price Target: $29
Current: $23.62
Upside: +22.80%
RAPT Therapeutics
Sep 21, 2022
Initiates: Overweight
Price Target: $384
Current: $10.90
Upside: +3,422.94%
Enanta Pharmaceuticals
May 12, 2022
Maintains: Buy
Price Target: $101 → $70
Current: $6.85
Upside: +921.90%
Rezolute
Sep 8, 2021
Initiates: Buy
Price Target: $21
Current: $6.20
Upside: +238.71%
Arvinas
Aug 9, 2021
Maintains: Buy
Price Target: $120 → $135
Current: $6.80
Upside: +1,886.75%
Daré Bioscience
Jun 30, 2021
Maintains: Buy
Price Target: $108 → $132
Current: $2.03
Upside: +6,402.46%
Ocugen
Jun 11, 2021
Downgrades: Neutral
Price Target: $10 → $6
Current: $1.03
Upside: +482.52%
Feb 18, 2021
Maintains: Buy
Price Target: $30 → $55
Current: $12.25
Upside: +348.98%
Aug 5, 2020
Initiates: Buy
Price Target: n/a
Current: $3.67
Upside: -
May 13, 2020
Initiates: Buy
Price Target: $8
Current: $0.43
Upside: +1,743.32%
Dec 18, 2019
Initiates: Buy
Price Target: $600
Current: $2.58
Upside: +23,155.81%